MarketCapExport financials
Navidea Biopharmaceuticals (NAVB)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Navidea Biopharmaceuticals Balance Sheet 2022-2008 | NAVB
Brief overview of Navidea Biopharmaceuticals's balance sheet structure
The comparison uses five available annual reports from the 2017–2021 interval.
Assets fell from $20.8 million to $6.6 million. This may reflect either deliberate optimization or a reduction in business scale.
Asset growth of -68% came with a -31.1% rise in liabilities. Financial leverage became more prominent.
Shareholders' capital is negative, making the balance sheet dependent on consistent debt servicing capacity.
Cash exceeds interest-bearing debt, producing net debt of -$3.9 million. The balance sheet therefore carries a net cash position.
Cash represents 63.7% of assets versus 13.4% initially, showing how the immediate liquidity reserve changed.
Retained earnings remain negative at -$370.8 million. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.
Balance sheet takeaway
Taken together, Navidea Biopharmaceuticals's balance sheet indicators point to elevated risk. Asset growth does not offset weak funding sources.
Annual Balance Sheet Navidea Biopharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-1.98 M | -3.93 M | -2.08 M | -284 K | -2.57 M | -441 K | 8.1 M | 53.6 M | 24.1 M | -9.37 M | -2.19 M | -22.2 M | - | - | - |
Long Term Debt |
1.31 K | 20.3 K | 296 K | 512 K | - | - | 9.64 M | 60.7 M | 29.5 M | 23.6 M | 6.93 M | 6.46 M | - | - | - |
Long Term Debt Current |
19 K | 276 K | 295 K | 251 K | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | 996 K | 1.21 M | 1.23 M | 665 K | 10.3 M | 62.6 M | 32.6 M | 33 M | 7.19 M | 6.71 M | - | - | - |
Total Current Liabilities |
9.94 M | 5.3 M | 4.72 M | 3.82 M | 3.38 M | 8.07 M | 69.9 M | 6.18 M | 9.06 M | 11.3 M | 6.19 M | 3.35 M | 3.94 M | - | - |
Total Liabilities |
12.5 M | 6.02 M | 5.71 M | 5.03 M | 4.61 M | 8.73 M | 80.1 M | 68.8 M | 41.6 M | 44.3 M | 13.4 M | 10.1 M | 6.73 M | - | - |
Deferred Revenue |
800 K | 40.8 K | 700 K | - | 867 K | - | 15 K | 1.04 M | - | - | - | - | - | - | - |
Retained Earnings |
-388 M | -371 M | -359 M | -348 M | -337 M | -320 M | -395 M | -381 M | -353 M | -317 M | -275 M | -245 M | -251 M | - | - |
Total Assets |
4.37 M | 6.64 M | 7.76 M | 4.15 M | 7.02 M | 20.8 M | 12.5 M | 15 M | 11.8 M | 40.3 M | 12 M | 31.2 M | 10.9 M | - | - |
Cash and Cash Equivalents |
2 M | 4.23 M | 2.67 M | 1.05 M | 3.48 M | 2.8 M | 1.54 M | 7.17 M | 5.48 M | 32.9 M | 9.12 M | 28.6 M | 6.42 M | 5.64 M | 3.57 M |
Book Value |
-8.14 M | 625 K | 2.05 M | -881 K | 2.41 M | 12 M | -67.7 M | -53.8 M | -29.8 M | -4.01 M | -1.41 M | 21.1 M | 4.13 M | - | - |
Total Shareholders Equity |
-8.44 M | -107 K | 1.32 M | -1.61 M | 1.74 M | 11.4 M | -68.1 M | -54.3 M | -29.8 M | -4.01 M | -1.41 M | 21.1 M | 4.13 M | -9.87 M | -3.03 M |
All numbers in USD currency
Quarterly Balance Sheet Navidea Biopharmaceuticals
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
269 | 534 | 926 | 1.31 K | 1.69 K | 2.06 K | 11.3 K | 20.3 K | 29 K | 120 K | 209 K | 296 K | 380 K | 434 K | 514 K | 512 K | 575 K | 614 K | 686 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
8.68 M | 9.01 M | 11.9 M | 12.5 M | 10.9 M | 6.74 M | 5.71 M | 6.02 M | 4.83 M | 4.85 M | 5.07 M | 5.71 M | 5.09 M | 5.28 M | 5.57 M | 5.03 M | 4.91 M | 5.2 M | 4.87 M | 4.61 M | 7.1 M | 5.87 M | 13.4 M | 8.73 M | 6.59 M | 8.56 M | 10.6 M | 80.1 M | 75 M | 72.6 M | 69.4 M | 68.8 M | 69.3 M | 66.8 M | 46.3 M | 41.6 M | 48.9 M | 47.4 M | 47.2 M | 44.3 M | 41.1 M | 33 M | 16.3 M | 13.4 M | 10.9 M | 10.1 M | 10 M | 10.1 M | 4.89 M | 5.91 M | 10.1 M |
Deferred Revenue |
800 K | 800 K | 800 K | 800 K | 800 K | - | - | - | - | - | - | - | - | - | - | - | - | 495 K | - | - | - | - | - | - | - | - | 15 K | 15 K | 15 K | 682 K | 945 K | 1.04 M | 1 M | 1 M | 1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 736 K | - |
Retained Earnings |
-386 M | -384 M | -389 M | -388 M | -385 M | -377 M | -374 M | -371 M | -367 M | -365 M | -362 M | -359 M | -356 M | -353 M | -350 M | -348 M | -345 M | -342 M | -339 M | -337 M | -334 M | -330 M | -327 M | -320 M | -316 M | -314 M | -309 M | -395 M | -391 M | -391 M | -384 M | -381 M | -378 M | -370 M | -360 M | -353 M | -346 M | -339 M | -329 M | -317 M | -304 M | -292 M | -282 M | -275 M | -267 M | -258 M | -252 M | -245 M | -238 M | -258 M | -245 M |
Total Assets |
5.7 M | 8.22 M | 2.37 M | 4.37 M | 6.26 M | 2.5 M | 3.6 M | 6.64 M | 8.96 M | 11.3 M | 10.1 M | 7.76 M | 6 M | 7.11 M | 4.48 M | 4.15 M | 4.82 M | 8.13 M | 4.96 M | 7.02 M | 9.11 M | 8.66 M | 18.3 M | 20.8 M | 22.6 M | 25.9 M | 32.9 M | 12.5 M | 11.2 M | 8.68 M | 12.3 M | 15 M | 17.5 M | 22.2 M | 10.9 M | 11.8 M | 17.6 M | 23.6 M | 32.6 M | 40.3 M | 49.9 M | 31.1 M | 13.6 M | 12 M | 13.6 M | 20 M | 24.7 M | 31.2 M | 33.4 M | 12 M | 31.2 M |
Cash and Cash Equivalents |
3.86 M | 6.14 M | 33.8 K | 2 M | 4.6 M | 328 K | 1.22 M | 4.23 M | 7.18 M | 7.11 M | 7.51 M | 2.67 M | 3.72 M | 1.62 M | 601 K | 1.05 M | 2.84 M | 5.06 M | 1.47 M | 3.48 M | 5.71 M | 4.69 M | 817 K | 2.8 M | 4.62 M | 5.63 M | 13.4 M | 1.54 M | 810 K | 1.16 M | 5.48 M | 7.17 M | 11.4 M | 15.8 M | 4.88 M | 5.48 M | 10.4 M | 17.5 M | 26 M | 32.9 M | 44.6 M | 25.6 M | 9.85 M | 9.12 M | 11.2 M | 17 M | 21.9 M | 28.6 M | 31.8 M | 7.54 M | 28.6 M |
Book Value |
-2.98 M | -787 K | -9.55 M | -8.14 M | -4.67 M | -4.24 M | -2.11 M | 625 K | 4.13 M | 6.44 M | 5.01 M | 2.05 M | 901 K | 1.83 M | -1.09 M | -881 K | -92.7 K | 2.93 M | 94.6 K | 2.41 M | 2.01 M | 2.79 M | 4.95 M | 12 M | 16 M | 17.3 M | 22.4 M | -67.7 M | -63.8 M | -63.9 M | -57.2 M | -53.8 M | -51.8 M | -44.6 M | -35.4 M | -29.8 M | -31.3 M | -23.8 M | -14.6 M | -4.01 M | 8.86 M | -1.83 M | -2.72 M | -1.41 M | 2.75 M | 9.93 M | 14.7 M | 21.1 M | 28.5 M | 6.08 M | 21.1 M |
Total Shareholders Equity |
-3.27 M | -1.08 M | -9.84 M | -8.44 M | -4.96 M | -4.53 M | -2.4 M | -107 K | 3.4 M | 5.7 M | 4.28 M | 1.32 M | 170 K | -2.35 M | -1.82 M | -1.61 M | -761 K | 2.26 M | -574 K | 1.74 M | 1.34 M | 2.12 M | 4.28 M | 11.4 M | 15.3 M | 16.7 M | 21.7 M | -68.1 M | -64.2 M | -64.4 M | -57.6 M | -54.3 M | -52.3 M | -45.1 M | -35.8 M | -29.8 M | -31.3 M | -23.8 M | -14.6 M | -4.01 M | 8.86 M | -1.83 M | -2.72 M | -1.41 M | 2.75 M | 9.93 M | 14.7 M | 21.1 M | 28.5 M | 6.08 M | 21.1 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Navidea Biopharmaceuticals, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Britain
Israel
Germany
Canada
Russia
Schweiz
